Rome, Nov 19. (Adnkronos Health) – “TtFields (Tumor Treating Fields) therapy for the treatment of newly diagnosed grade 4 glioma has won the Prix Galien Italia 2026 in the Digital Health, Medical Devices and Innovation category”. Novocure announced this today in a note, highlighting that the 2026 edition introduced “a significant novelty: the establishment of a category dedicated to medical devices and digital health”, with a dedicated evaluation committee coordinated by Fabrizio Gervasoni, editor-in-chief of ‘Gihtad’, Italian Journal of Health Technology Assessment Delivery, and coordinator of the Hta/Innovation Commission of Omceo – Order of Physicians of Milan, with the scientific contribution of Roberto Carlo Rossi, co-editor-in-chief of Gihtad and president of Omceo of Milan. “The Prix Galien Italia has always recognized excellence in pharmacological research and its ability to transform scientific progress into concrete opportunities for patients – states Pier Luigi Canonico, president of the jury – Because true innovation is what tangibly changes the way we treat patients. With the new category dedicated to medical devices, the Prix Galien Italia emphasizes the value generated throughout the entire therapeutic pathway, also through technology.”
“We are honored and proud to have received this prestigious recognition: a significant milestone,” comments Patrizia Pisarra, Country Manager and legal representative of Novocure Italia. Tumor Treating Fields therapy – explains the company – is made possible by a Class IIb medical device with CE mark (CE-0197), indicated for the treatment of grade 4 gliomas (according to the WHO classification, World Health Organization), in newly diagnosed adult patients. It is a non-invasive physical therapy based on Tumor Treating Fields, alternating electric fields of low intensity and intermediate frequency, which interfere with the division of tumor cells by exploiting their specific electrical and geometric-spatial properties, acting selectively on tumor cells and sparing healthy ones. It is the first treatment since 2005 to have demonstrated an increase in overall survival in these patients, without systemic side effects.
The portable and non-invasive device – Novocure describes – allows the patient to continue with normal daily activities. The treatment, administered at home continuously (≥18 hours/day), involves applying patches containing electrodes (arrays) to the patient’s shaved head; these are then connected via a cable to a small battery-powered generator, which is carried in a bag or backpack. The new transducer arrays – lightweight, thin, and flexible – incorporate thermal safety sensors and automatically record data related to treatment adherence, which are transmitted monthly to the specialist who prescribed the therapy.